Abstract
Background Trinucleotide repeat expansions are an emerging class of genetic variants associated with several movement disorders. Unbiased genome-wide analyses can reveal novel genotype-phenotype associations and provide a diagnosis for patients and families.
Objectives To identify the genetic cause of a severe progressive movement disorder phenotype in two affected brothers.
Methods A family of two affected brothers and unaffected parents had extensive phenotyping and natural history followed since birth. Whole-genome and long-read sequencing methods were used to characterize genetic variants and methylation status. Results: We describe a CGG repeat expansion in the 5’-untranslated region of DIP2B in two affected male siblings presenting with a novel DIP2B phenotype including neurodevelopmental disability, dysmorphic traits, and a severe progressive movement disorder (prominent chorea, dystonia, and ataxia).
Conclusions This is the first report of a severe progressive movement disorder phenotype attributed to a CGG repeat expansion in the DIP2B 5’-UTR.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants awarded to C.V.K. and A.L. from the Canadian Institutes of Health Research, GenomeCanada and GenomeBC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of British Columbia clinical research ethics board gave ethical approval for this work under applications H12-00067 and H18-02912.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial Disclosure / Conflict of Interest Statement There are no financial disclosures or conflicts of interest reported by the authors related to the present manuscript.
Funding Sources This work was supported by grants awarded to C.V.K. and A.L. from the Canadian Institutes of Health Research, GenomeCanada and GenomeBC (University of British Columbia clinical research ethics board applications H12-00067 and H18-02912).
Data Availability
Upon approval from the Care4Rare Canada Consortium, deidentified participant data with study accession numbers (Project 3058, samples BC200-203) may be available through access to Genomics4RD (genomics4rd.ca).
